Short answer
ASP Isotopes Inc. (ASPI) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Press release contains forward-looking statements subject to material risks and uncertainties.
ASP Isotopes Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Press release contains forward-looking statements subject to material risks and uncertainties
- Investors should rely on the company’s Form 10-K and SEC filings for risk factors
- No obligation to update projections for subsequent information or events
Item EX-99.1 · Exhibit EX-99.1
- Capital Markets Day signals transition from development to early commercialization across nuclear medicine, helium, LNG, electronics and nuclear fuels
- Revenue catalysts include Phase 1 liquid helium production, radiopharmacy growth and first commercial stable-isotope shipments over the next 12 months
- Management targets more than $300 million EBITDA in 2031, a long-term non-GAAP goal dependent on substantial execution and commercialization
- Proposed separate public listings for Quantum Leap Energy and Noble Africa could unlock business-level financing and valuation, but remain uncertain
- Forward-looking plans face funding, regulatory, construction and transaction-completion risks, including uranium-enrichment approvals and Noble Africa’s reverse merger
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ASP Isotopes Inc. 8-K filings
Get the next ASPI 8-K as it lands
Follow ASPI for push alerts, or ask the research agent what this filing means.